Breast Cancer Diagnostics Market Size, Trends, and Insights By Type (Imaging, Genomic Tests, Biopsy, Blood Tests, Others), By Product (Platform-based Products, Next-generation Sequencing, PCR, Microarrays, Others, Instrument-based Products, Biopsy, Imaging), By Application (Screening, Prognostic, Diagnostic and Predictive, Research), By End-use (Diagnostic Centers and Medical Laboratories, Hospitals & Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2023–2032
Report Snapshot
Study Period: | 2022-2030 |
Fastest Growing Market: | Asia-Pacific |
Largest Market: | Europe |
Major Players
- Hologic Inc.
- Thermo Fisher Scientific Inc.
- BD
- Genomic Health (Exact Sciences Corporation)
- Others
Reports Description
According to Custom Market Insights (CMI), the Global Breast Cancer Diagnostics Market size was estimated at USD 5 Billion in 2021 and is expected to reach USD 5.2 billion in 2022 and is expected to hit around USD 7.5 Billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 6% from 2022 to 2030.
Our research report offers a 360-degree view of the Breast Cancer Diagnostics market’s drivers and restraints, coupled with the impact they have on demand during the projection period. Also, the report examines global opportunities and competitive analysis for the Breast Cancer Diagnostics market.
- Breast glandular tissue’s ducts or lobules contain living cells that are the origin of breast cancer. The malignant development initially only affects the duct or lobule, where it is unlikely to spread and frequently exhibits no signs.
- Treatments for breast cancer can be highly effective, particularly if the disease is discovered early. Treatment options for small cancer that has spread from a breast tumour through the bloodstream often include radiation therapy, medication, and surgery. This type of treatment can stop the development and spread of cancer, thereby saving lives.
- The World Health Organization (WHO) estimates that 2.3 million women worldwide were affected by breast cancer in 2020, with 6,85,000 deaths. Breast cancer would have been diagnosed in 7.8 million women by the end of 2020, making it the most common cancer worldwide. Due to the increasing prevalence of the condition, the global market for breast cancer diagnostics will grow throughout the projection period.
- Breast cancer tumours are among the most challenging to identify and cure because they are frequently discovered after they have developed to an advanced stage. As people look for more efficient diagnostic treatments to manage the condition effectively, the necessity for early breast cancer diagnosis is growing. the application of screening, imaging, and other diagnostic techniques.
- The COVID-19 pandemic has significantly harmed all medical operations and healthcare institutions since it was declared a global pandemic in 2020. Many women neglected to get their routine mammograms, which had a negative effect on the breast screening industry. Since an increasing number of women are skipping breast cancer screening appointments, there is a real concern that many more women may develop breast cancer in its advanced stages in the future year. Notwithstanding the increased pressure on hospitals and screening facilities to accommodate the rising number of women in need of breast cancer screening, a sizable investment in medical staff and breast screening equipment will be needed to help solve the patient backlog.
Report Scope
The global market research study for breast cancer diagnostics provides a detailed analysis of the global market size, which is further divided into regional and national market sizes, as well as market segmentation growth. Additionally, it offers information on market share, sales analysis, the competitive environment, the influence of domestic and international market players, trade regulations, value chain optimization, recent significant developments, strategic market growth analysis, opportunities analysis, product launches, and technological innovations. Market size and forecasting for segmentation by type, product, application, end-use, and geography are included in the study’s scope.
Feature of the Report | Details |
Market Size in 2021 | USD 5 Billion |
Projected Market Size in 2030 | USD 7.5 Billion |
Market Size in 2022 | USD 5.2 Billion |
CAGR Growth Rate | 6% CAGR (2022-2030) |
Base Year | 2022 |
Forecast Period | 2023-2032 |
Prominent Players | Hologic Inc., Thermo Fisher Scientific Inc., BD, Genomic Health (Exact Sciences Corporation), Danaher, Koninklijke Philips N.V., QIAGEN, Myriad Genetics, F. Hoffmann-La Roche Ltd., Argon Medical Devices Inc., and Others |
Key Segment | By Type, Product, Application, End-use, and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors, and Recent Trends |
Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
Buying Options | Request tailored purchasing options to fulfill your requirements for research. |
Key Market Dynamics
- The rise in government initiatives to increase the rate of screening and diagnosis, along with the rising cancer prevalence, may be a key factor in the expansion of the global market for breast cancer diagnostics. The rising incidence of breast cancer is expected to drive the market for breast cancer diagnostics. According to the American Cancer Society, there will be 281,550 new cases of breast cancer discovered in 2021, and the disease will claim 49,290 lives in just the United States. Breast cancer will surpass 2.3 million new cases in 2021, making it the most common type of cancer globally, predicts the WHO.
- The increased need for technologically advanced products that can provide more precision, speed, and cost-effectiveness is projected to be the main growth factor during the course of the projection period. Take the development of Direct-To-Consumer (DTC) testing for cancer diagnosis as an example. The first direct-to-consumer (DTC) BRCA test, introduced by 23andMe in 2018, received FDA approval in the United States. One of the first DTC examinations for BRCA gene abnormalities that increase the risk of breast and ovarian cancer.
- Additionally, it is expected that the improved pay and insurance coverage will quicken the adoption of testing. Several tests have received approval from government bodies for nationwide reimbursement. Medicaid, Medicare, and third-party payer benefit plans in the United States will pay for the cost of genetic testing.
- Early disease detection is essential for effective disease management. It can improve survival rates, provide a range of therapeutic alternatives, and result in an improved quality of life. Regular mammography screening and early detection can lower the breast cancer rate by 30%, claims a 2018 Research Quick Facts article. Research being done to develop tests that can detect breast cancer as early as feasible is expected to lead to an increase in the market for breast cancer diagnostics.
North America Led the Breast Cancer Diagnostics Market
- The key forces behind this region’s domination include the existence of significant players, established diagnostic & screening infrastructure, technological advancements, high patient awareness, and alluring reimbursement policies.
- North America had the top position in the global market for cancer diagnostics due to its concentrated oncology continuing research for the development of early tumour detection techniques and support from government healthcare organisations. This status is a testament to the area’s robust medical system in the fight against cancer. Also, the market expansion has been aided by the growth of biotechnology and medical device businesses, greater financing for R&D initiatives, and the quick uptake of novel technologies in this area.
- One of the key reasons why the death rate for cancer patients in the US has decreased is early diagnosis. The region’s access to qualified technicians is one of the major factors impacting the market’s expansion. The market is also expanding as a result of extensive research and development as well as adequate funding.
Competitive Landscape
The leading market players strengthen their product portfolios using both organic and inorganic expansion techniques. To stay competitive in the global market for breast cancer diagnostics, these companies have used tactics such geographic growth, joint ventures, acquisitions, investments in research & development, and manufacture of cutting-edge breast cancer diagnostic technologies.
- Hologic Inc. acquired Biotheranostics and SOMATEX Medical Technologies GmbH in 2021. By acquiring these companies, the company expanded its line of breast health products and enhanced its position in the breast cancer diagnostics market.
- 2020: To develop cutting-edge clinical biomarkers, Thermo Fisher Scientific, Inc. has teamed up with AstraZeneca and the University of Nebraska Medical Center.
Prominent Players:
- Hologic Inc.
- Thermo Fisher Scientific Inc.
- BD
- Genomic Health (Exact Sciences Corporation)
- Danaher
- Koninklijke Philips N.V.
- QIAGEN
- Myriad Genetics
- Hoffmann-La Roche Ltd.
- Argon Medical Devices Inc.
The global Breast Cancer Diagnostics market is segmented as follows:
By Type
- Imaging
- Genomic Tests
- Biopsy
- Blood Tests
- Others
By Product
- Platform-based Products
- Next-generation Sequencing
- PCR
- Microarrays
- Others
- Instrument-based Products
- Biopsy
- Imaging
By Application
- Screening
- Prognostic
- Diagnostic and Predictive
- Research
By End-use
- Diagnostic Centers and Medical Laboratories
- Hospitals & Clinics
- Others
By Region
North America
- The U.S.
- Canada
- Mexico
Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Breast Cancer Diagnostics Market, (2022 – 2030) (USD Billion)
- 2.2 Global Breast Cancer Diagnostics Market : snapshot
- Chapter 3. Global Breast Cancer Diagnostics Market – Industry Analysis
- 3.1 Breast Cancer Diagnostics Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 The aging population
- 3.2.2 The rising number of breast cancer cases in women around the world.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Type
- 3.7.2 Market attractiveness analysis By Product
- 3.7.3 Market attractiveness analysis By Application
- 3.7.4 Market attractiveness analysis By End-use
- Chapter 4. Global Breast Cancer Diagnostics Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Breast Cancer Diagnostics Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Breast Cancer Diagnostics Market – Type Analysis
- 5.1 Global Breast Cancer Diagnostics Market overview: By Type
- 5.1.1 Global Breast Cancer Diagnostics Market share, By Type, 2021 and 2030
- 5.2 Imaging
- 5.2.1 Global Breast Cancer Diagnostics Market by Imaging, 2022 – 2030 (USD Billion)
- 5.3 Genomic Tests
- 5.3.1 Global Breast Cancer Diagnostics Market by Genomic Tests, 2022 – 2030 (USD Billion)
- 5.4 Biopsy
- 5.4.1 Global Breast Cancer Diagnostics Market by Biopsy, 2022 – 2030 (USD Billion)
- 5.5 Blood Tests
- 5.5.1 Global Breast Cancer Diagnostics Market by Blood Tests, 2022 – 2030 (USD Billion)
- 5.6 Others
- 5.6.1 Global Breast Cancer Diagnostics Market by Others, 2022 – 2030 (USD Billion)
- 5.1 Global Breast Cancer Diagnostics Market overview: By Type
- Chapter 6. Global Breast Cancer Diagnostics Market – Product Analysis
- 6.1 Global Breast Cancer Diagnostics Market overview: By Product
- 6.1.1 Global Breast Cancer Diagnostics Market share, By Product, 2021 and 2030
- 6.2 Platform-based Products
- 6.2.1 Global Breast Cancer Diagnostics Market by Platform-based Products, 2022 – 2030 (USD Billion)
- 6.3 Next-generation Sequencing
- 6.3.1 Global Breast Cancer Diagnostics Market by Next-generation Sequencing, 2022 – 2030 (USD Billion)
- 6.4 PCR
- 6.4.1 Global Breast Cancer Diagnostics Market by PCR, 2022 – 2030 (USD Billion)
- 6.5 Microarrays
- 6.5.1 Global Breast Cancer Diagnostics Market by Microarrays, 2022 – 2030 (USD Billion)
- 6.6 Others
- 6.6.1 Global Breast Cancer Diagnostics Market by Others, 2022 – 2030 (USD Billion)
- 6.7 Instrument-based Products
- 6.7.1 Global Breast Cancer Diagnostics Market by Instrument-based Products, 2022 – 2030 (USD Billion)
- 6.8 Biopsy
- 6.8.1 Global Breast Cancer Diagnostics Market by Biopsy, 2022 – 2030 (USD Billion)
- 6.9 Imaging
- 6.9.1 Global Breast Cancer Diagnostics Market by Imaging, 2022 – 2030 (USD Billion)
- 6.1 Global Breast Cancer Diagnostics Market overview: By Product
- Chapter 7. Global Breast Cancer Diagnostics Market – Application Analysis
- 7.1 Global Breast Cancer Diagnostics Market overview: By Application
- 7.1.1 Global Breast Cancer Diagnostics Market share, By Application, 2021 and 2030
- 7.2 Screening
- 7.2.1 Global Breast Cancer Diagnostics Market by Screening, 2022 – 2030 (USD Billion)
- 7.3 Prognostic
- 7.3.1 Global Breast Cancer Diagnostics Market by Prognostic, 2022 – 2030 (USD Billion)
- 7.4 Diagnostic and Predictive
- 7.4.1 Global Breast Cancer Diagnostics Market by Diagnostic and Predictive, 2022 – 2030 (USD Billion)
- 7.5 Research
- 7.5.1 Global Breast Cancer Diagnostics Market by Research, 2022 – 2030 (USD Billion)
- 7.1 Global Breast Cancer Diagnostics Market overview: By Application
- Chapter 8. Global Breast Cancer Diagnostics Market – End-use Analysis
- 8.1 Global Breast Cancer Diagnostics Market overview: By End-use
- 8.1.1 Global Breast Cancer Diagnostics Market share, By End-use, 2021 and 2030
- 8.2 Diagnostic Centers and Medical Laboratories
- 8.2.1 Global Breast Cancer Diagnostics Market by Diagnostic Centers and Medical Laboratories, 2022 – 2030 (USD Billion)
- 8.3 Hospitals & Clinics
- 8.3.1 Global Breast Cancer Diagnostics Market by Hospitals & Clinics, 2022 – 2030 (USD Billion)
- 8.4 Others
- 8.4.1 Global Breast Cancer Diagnostics Market by Others, 2022 – 2030 (USD Billion)
- 8.1 Global Breast Cancer Diagnostics Market overview: By End-use
- Chapter 9. Breast Cancer Diagnostics Market – Regional Analysis
- 9.1 Global Breast Cancer Diagnostics Market Regional Overview
- 9.2 Global Breast Cancer Diagnostics Market Share, by Region, 2021 & 2030 (USD Billion)
- 9.3. North America
- 9.3.1 North America Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.3.1.1 North America Breast Cancer Diagnostics Market, by Country, 2022 – 2030 (USD Billion)
- 9.3.1 North America Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.4 North America Breast Cancer Diagnostics Market, by Type, 2022 – 2030
- 9.4.1 North America Breast Cancer Diagnostics Market, by Type, 2022 – 2030 (USD Billion)
- 9.5 North America Breast Cancer Diagnostics Market, by Product, 2022 – 2030
- 9.5.1 North America Breast Cancer Diagnostics Market, by Product, 2022 – 2030 (USD Billion)
- 9.6 North America Breast Cancer Diagnostics Market, by Application, 2022 – 2030
- 9.6.1 North America Breast Cancer Diagnostics Market, by Application, 2022 – 2030 (USD Billion)
- 9.7 North America Breast Cancer Diagnostics Market, by End-use, 2022 – 2030
- 9.7.1 North America Breast Cancer Diagnostics Market, by End-use, 2022 – 2030 (USD Billion)
- 9.8. Europe
- 9.8.1 Europe Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.8.1.1 Europe Breast Cancer Diagnostics Market, by Country, 2022 – 2030 (USD Billion)
- 9.8.1 Europe Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.9 Europe Breast Cancer Diagnostics Market, by Type, 2022 – 2030
- 9.9.1 Europe Breast Cancer Diagnostics Market, by Type, 2022 – 2030 (USD Billion)
- 9.10 Europe Breast Cancer Diagnostics Market, by Product, 2022 – 2030
- 9.10.1 Europe Breast Cancer Diagnostics Market, by Product, 2022 – 2030 (USD Billion)
- 9.11 Europe Breast Cancer Diagnostics Market, by Application, 2022 – 2030
- 9.11.1 Europe Breast Cancer Diagnostics Market, by Application, 2022 – 2030 (USD Billion)
- 9.12 Europe Breast Cancer Diagnostics Market, by End-use, 2022 – 2030
- 9.12.1 Europe Breast Cancer Diagnostics Market, by End-use, 2022 – 2030 (USD Billion)
- 9.13. Asia Pacific
- 9.13.1 Asia Pacific Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.13.1.1 Asia Pacific Breast Cancer Diagnostics Market, by Country, 2022 – 2030 (USD Billion)
- 9.13.1 Asia Pacific Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.14 Asia Pacific Breast Cancer Diagnostics Market, by Type, 2022 – 2030
- 9.14.1 Asia Pacific Breast Cancer Diagnostics Market, by Type, 2022 – 2030 (USD Billion)
- 9.15 Asia Pacific Breast Cancer Diagnostics Market, by Product, 2022 – 2030
- 9.15.1 Asia Pacific Breast Cancer Diagnostics Market, by Product, 2022 – 2030 (USD Billion)
- 9.16 Asia Pacific Breast Cancer Diagnostics Market, by Application, 2022 – 2030
- 9.16.1 Asia Pacific Breast Cancer Diagnostics Market, by Application, 2022 – 2030 (USD Billion)
- 9.17 Asia Pacific Breast Cancer Diagnostics Market, by End-use, 2022 – 2030
- 9.17.1 Asia Pacific Breast Cancer Diagnostics Market, by End-use, 2022 – 2030 (USD Billion)
- 9.18. Latin America
- 9.18.1 Latin America Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.18.1.1 Latin America Breast Cancer Diagnostics Market, by Country, 2022 – 2030 (USD Billion)
- 9.18.1 Latin America Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.19 Latin America Breast Cancer Diagnostics Market, by Type, 2022 – 2030
- 9.19.1 Latin America Breast Cancer Diagnostics Market, by Type, 2022 – 2030 (USD Billion)
- 9.20 Latin America Breast Cancer Diagnostics Market, by Product, 2022 – 2030
- 9.20.1 Latin America Breast Cancer Diagnostics Market, by Product, 2022 – 2030 (USD Billion)
- 9.21 Latin America Breast Cancer Diagnostics Market, by Application, 2022 – 2030
- 9.21.1 Latin America Breast Cancer Diagnostics Market, by Application, 2022 – 2030 (USD Billion)
- 9.22 Latin America Breast Cancer Diagnostics Market, by End-use, 2022 – 2030
- 9.22.1 Latin America Breast Cancer Diagnostics Market, by End-use, 2022 – 2030 (USD Billion)
- 9.23. The Middle-East and Africa
- 9.23.1 The Middle-East and Africa Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.23.1.1 The Middle-East and Africa Breast Cancer Diagnostics Market, by Country, 2022 – 2030 (USD Billion)
- 9.23.1 The Middle-East and Africa Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 9.24 The Middle-East and Africa Breast Cancer Diagnostics Market, by Type, 2022 – 2030
- 9.24.1 The Middle-East and Africa Breast Cancer Diagnostics Market, by Type, 2022 – 2030 (USD Billion)
- 9.25 The Middle-East and Africa Breast Cancer Diagnostics Market, by Product, 2022 – 2030
- 9.25.1 The Middle-East and Africa Breast Cancer Diagnostics Market, by Product, 2022 – 2030 (USD Billion)
- 9.26 The Middle-East and Africa Breast Cancer Diagnostics Market, by Application, 2022 – 2030
- 9.26.1 The Middle-East and Africa Breast Cancer Diagnostics Market, by Application, 2022 – 2030 (USD Billion)
- 9.27 The Middle-East and Africa Breast Cancer Diagnostics Market, by End-use, 2022 – 2030
- 9.27.1 The Middle-East and Africa Breast Cancer Diagnostics Market, by End-use, 2022 – 2030 (USD Billion)
- Chapter 10. Company Profiles
- 10.1 Hologic Inc.
- 10.1.1 Overview
- 10.1.2 Financials
- 10.1.3 Product Portfolio
- 10.1.4 Business Strategy
- 10.1.5 Recent Developments
- 10.2 Thermo Fisher Scientific Inc.
- 10.2.1 Overview
- 10.2.2 Financials
- 10.2.3 Product Portfolio
- 10.2.4 Business Strategy
- 10.2.5 Recent Developments
- 10.3 BD
- 10.3.1 Overview
- 10.3.2 Financials
- 10.3.3 Product Portfolio
- 10.3.4 Business Strategy
- 10.3.5 Recent Developments
- 10.4 Genomic Health (Exact Sciences Corporation)
- 10.4.1 Overview
- 10.4.2 Financials
- 10.4.3 Product Portfolio
- 10.4.4 Business Strategy
- 10.4.5 Recent Developments
- 10.5 Danaher
- 10.5.1 Overview
- 10.5.2 Financials
- 10.5.3 Product Portfolio
- 10.5.4 Business Strategy
- 10.5.5 Recent Developments
- 10.6 Koninklijke Philips N.V.
- 10.6.1 Overview
- 10.6.2 Financials
- 10.6.3 Product Portfolio
- 10.6.4 Business Strategy
- 10.6.5 Recent Developments
- 10.7 QIAGEN
- 10.7.1 Overview
- 10.7.2 Financials
- 10.7.3 Product Portfolio
- 10.7.4 Business Strategy
- 10.7.5 Recent Developments
- 10.8 Myriad Genetics
- 10.8.1 Overview
- 10.8.2 Financials
- 10.8.3 Product Portfolio
- 10.8.4 Business Strategy
- 10.8.5 Recent Developments
- 10.9 F. Hoffmann-La Roche Ltd.
- 10.9.1 Overview
- 10.9.2 Financials
- 10.9.3 Product Portfolio
- 10.9.4 Business Strategy
- 10.9.5 Recent Developments
- 10.10 Argon Medical Devices Inc.
- 10.10.1 Overview
- 10.10.2 Financials
- 10.10.3 Product Portfolio
- 10.10.4 Business Strategy
- 10.10.5 Recent Developments
- 10.1 Hologic Inc.
List Of Figures
- 1. Market research Type
- 2. Market research methodology
- 3. Global Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 4. Porter’s Five Forces Analysis
- 5. Global Breast Cancer Diagnostics Market attractiveness, By Type
- 6. Global Breast Cancer Diagnostics Market attractiveness, By Product
- 7. Global Breast Cancer Diagnostics Market attractiveness, By Application
- 8. Global Breast Cancer Diagnostics Market attractiveness, By End-use
- 9. Global Breast Cancer Diagnostics Market share by Type, 2022 and 2030 (USD Billion)
- 10. Global Breast Cancer Diagnostics Market by Imaging, 2022 – 2030 (USD Billion)
- 11. Global Breast Cancer Diagnostics Market by Genomic Tests, 2022 – 2030 (USD Billion)
- 12. Global Breast Cancer Diagnostics Market by Biopsy, 2022 – 2030 (USD Billion)
- 13. Global Breast Cancer Diagnostics Market by Blood Tests, 2022 – 2030 (USD Billion)
- 14. Global Breast Cancer Diagnostics Market by Others, 2022 – 2030 (USD Billion)
- 15. Global Breast Cancer Diagnostics Market share by Product, 2022 and 2030 (USD Billion)
- 16. Global Breast Cancer Diagnostics Market by Platform-based Products, 2022 – 2030 (USD Billion)
- 17. Global Breast Cancer Diagnostics Market by Next-generation Sequencing, 2022 – 2030 (USD Billion)
- 18. Global Breast Cancer Diagnostics Market by PCR, 2022 – 2030 (USD Billion)
- 19. Global Breast Cancer Diagnostics Market by Microarrays, 2022 – 2030 (USD Billion)
- 20. Global Breast Cancer Diagnostics Market by Others, 2022 – 2030 (USD Billion)
- 21. Global Breast Cancer Diagnostics Market by Instrument-based Products, 2022 – 2030 (USD Billion)
- 22. Global Breast Cancer Diagnostics Market by Biopsy, 2022 – 2030 (USD Billion)
- 23. Global Breast Cancer Diagnostics Market by Imaging, 2022 – 2030 (USD Billion)
- 24. Global Breast Cancer Diagnostics Market share by Application, 2022 and 2030 (USD Billion)
- 25. Global Breast Cancer Diagnostics Market by Screening, 2022 – 2030 (USD Billion)
- 26. Global Breast Cancer Diagnostics Market by Prognostic, 2022 – 2030 (USD Billion)
- 27. Global Breast Cancer Diagnostics Market by Diagnostic and Predictive, 2022 – 2030 (USD Billion)
- 28. Global Breast Cancer Diagnostics Market by Research, 2022 – 2030 (USD Billion)
- 29. Global Breast Cancer Diagnostics Market share by End-use, 2022 and 2030 (USD Billion)
- 30. Global Breast Cancer Diagnostics Market by Diagnostic Centers and Medical Laboratories, 2022 – 2030 (USD Billion)
- 31. Global Breast Cancer Diagnostics Market by Hospitals & Clinics, 2022 – 2030 (USD Billion)
- 32. Global Breast Cancer Diagnostics Market by Others, 2022 – 2030 (USD Billion)
- 33. Global Breast Cancer Diagnostics Market share, by Region, 2022 and 2030
- 34. North America Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 35. Europe Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 36. Asia Pacific Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 37. Latin America Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
- 38. The Middle-East and Africa Breast Cancer Diagnostics Market, 2022 – 2030 (USD Billion)
List Of Tables
- 1. Global Breast Cancer Diagnostics Market: Snapshot
- 2. Drivers of the Breast Cancer Diagnostics Market: impact analysis
- 3. North America Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 4. North America Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 5. North America Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 6. North America Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 7. U.S. Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 8. U.S. Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 9. U.S. Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 10. U.S. Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 11. Canada Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 12. Canada Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 13. Canada Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 14. Canada Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 15. Europe Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 16. Europe Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 17. Europe Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 18. Europe Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 19. Germany Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 20. Germany Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 21. Germany Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 22. Germany Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 23. France Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 24. France Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 25. France Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 26. France Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 27. U.K. Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 28. U.K. Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 29. U.K. Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 30. U.K. Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 31. Italy Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 32. Italy Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 33. Italy Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 34. Italy Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 35. Spain Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 36. Spain Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 37. Spain Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 38. Spain Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 39. Rest of Europe Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 40. Rest of Europe Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 41. Rest of Europe Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 42. Rest of Europe Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 43. Asia Pacific Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 44. Asia Pacific Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 45. Asia Pacific Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 46. Asia Pacific Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 47. China Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 48. China Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 49. China Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 50. China Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 51. Japan Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 52. Japan Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 53. Japan Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 54. Japan Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 55. India Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 56. India Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 57. India Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 58. India Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 59. South Korea Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 60. South Korea Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 61. South Korea Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 62. South Korea Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 63. South-East Asia Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 64. South-East Asia Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 65. South-East Asia Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 66. South-East Asia Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 67. Rest of Asia Pacific Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 68. Rest of Asia Pacific Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 69. Rest of Asia Pacific Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 70. Rest of Asia Pacific Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 71. Latin America Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 72. Latin America Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 73. Latin America Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 74. Latin America Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 75. Brazil Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 76. Brazil Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 77. Brazil Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 78. Brazil Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 79. Mexico Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 80. Mexico Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 81. Mexico Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 82. Mexico Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 83. Rest of Latin America Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 84. Rest of Latin America Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 85. Rest of Latin America Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 86. Rest of Latin America Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 87. The Middle-East and Africa Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 88. The Middle-East and Africa Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 89. The Middle-East and Africa Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 90. The Middle-East and Africa Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 91. GCC Countries Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 92. GCC Countries Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 93. GCC Countries Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 94. GCC Countries Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 95. South Africa Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 96. South Africa Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 97. South Africa Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 98. South Africa Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
- 99. Rest of Middle-East Africa Breast Cancer Diagnostics Market revenue, By Type, 2022 – 2030 (USD Billion)
- 100. Rest of Middle-East Africa Breast Cancer Diagnostics Market revenue, By Product, 2022 – 2030 (USD Billion)
- 101. Rest of Middle-East Africa Breast Cancer Diagnostics Market revenue, By Application, 2022 – 2030 (USD Billion)
- 102. Rest of Middle-East Africa Breast Cancer Diagnostics Market revenue, By End-use, 2022 – 2030 (USD Billion)
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2030
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
Perspective | Primary research | Secondary research |
Supply-side |
|
|
Demand-side |
|
|
Market Analysis Matrix
Qualitative analysis | Quantitative analysis |
|
|
FAQs
“Asia Pacific” region will lead the global Breast Cancer Diagnostics market during the forecast period 2022 to 2030.
The key factors driving the market are the aging population and the rising number of breast cancer cases in women around the world.
The key players operating in the Breast Cancer Diagnostics market are Hologic Inc., Thermo Fisher Scientific Inc., BD, Genomic Health (Exact Sciences Corporation), Danaher, Koninklijke Philips N.V., QIAGEN, Myriad Genetics, F. Hoffmann-La Roche Ltd., Argon Medical Devices Inc.
The global Breast Cancer Diagnostics market is expanding growth with a CAGR of approximately 6% during the forecast period (2022 to 2030).
The global Breast Cancer Diagnostics market size was valued at USD 5 Billion in 2021 and it is projected to reach around USD 7.5 Billion by 2030.